Merck KGaA is a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 40,000 employees in 67 countries. Merck KGaA's subsidiaries in North America operate using the umbrella brand "EMD". More
Wednesday, Sep 257:35 AMMerck to take Oncothyreon cancer drug into new Phase III trial
Wednesday, Sep 257:35 AM| 1 Comment
- Oncothyreon (ONTY) surges 29% after saying that Merck KGa (MKGAF.PK) intends to carry out a Phase III trial of Oncothyreon's tecemotide immunotherapy in patients with advanced non-small cell lung cancer.
- While tecemotide failed to meet the primary goal of a previous trial of improving survival in the overall patient population, the drug did achieve survival times 30.8 months vs 20.6 months for a placebo in a sub-group. (PR)
Wednesday, Aug 79:09 AMTcelna speculation possibly driving Opexa gains
Wednesday, Aug 79:09 AM| 7 Comments
- The rumor mill is abuzz: Comments from Merck KGaA (MKGAF.PK) regarding a 2-3% market share loss (transcript) for the MS treatment Rebif at the hands of Biogen's Tecfidera are fueling speculation that the German drug and materials company may heighten its focus on Tcelna, a treatment for Secondary Progressive MS being developed in conjunction with Opexa Therapeutics (OPXA).
- Shares of OPXA are now up 57% before the bell.
Wednesday, Dec 192012, 8:39 AMStimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) |Wednesday, Dec 192012, 8:39 AM| Comment!
Tuesday, Oct 162012, 9:01 AM
Tuesday, Mar 62012, 6:52 AMShares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK) announces that studies on the experimental lung-cancer drug Stimuvax won't be completed until next year. Stimuvax is being developed by Merck KGaA under a license agreement with Oncothyreon. |Tuesday, Mar 62012, 6:52 AM| Comment!
Friday, Feb 32012, 7:39 AMShares of Threshold Pharmaceuticals (THLD) skyrocket, up 62.1%, after the biotech firm announces that it landed a deal with Merck KGaA (MKGAF.PK) to co-develop and commercialize its TH-302 cancer treatment drug. Props to M. E. Garza who nailed this call in December. |Friday, Feb 32012, 7:39 AM| Comment!